HeyJaredThe Clinical Trials Abundance blog
Ideas, thoughts and commentary on how to make clinical trials more efficient.
- Indexed issues, last 90 days
- 4
- Latest publication
- Sep 25, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 14, 2026
Latest issues
The clinical trial bottlenecks game (opens the original)
Read excerpt
Happy Friday! I’ve created a little game called ‘The clinical trial bottlenecks game’. Naturally, it’s bottle-themed, with bubbles and literal bottlenecks. And there are leaderboards as well. You can simply go and play the game instead of reading this post. But if you want to stick around, I’ll describe the motivation behind it, some of my takeaways, and what it tells us about whether AI will cure all diseases in ten years. (For real.)<a class="ima
Clinical Trial Abundance in the New York Times (opens the original)
Read excerpt
In case you missed it, the cause of Clinical Trial Abundance just received a high–profile boost in the New York Times, in the form of a compelling article from our co-blogger Ruxandra Teslo. Along with the New York Times article, Ruxandra and I have also published a companion piece for the Institute for Progress describing what we can learn from Australia’s approach to clinical trial regulation,
Google Maps for Medicines (opens the original)
Read excerpt
Google Maps was launched in 2005. It is hard to imagine life before that little blue dot. You either memorised your daily routes (which were not necessarily optimal) or traced a new route on a map, which sometimes resulted in driving your caravan down a cobbled French street narrower than a baguette.Navigation is hard, and it gets harder as the number of transport options grows. When your only option was to walk, journeys were slow but decisions were simple. But then came planes, trains, and aut
Market shaping and trial design belong together (opens the original)
Read excerpt
In the clinical trials world, many of us are interested in ways of designing faster and better trials. Meanwhile, our colleagues in economics and global health work on using market shaping to deliver innovations where the private companies don’t have a profit motive: for repurposing of generic drugs. Talking to both groups, it gradually dawned on me that both groups are solving very similar problems.I recently wrote a 2,000 word note for funders that explains why I think market design ideas and
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.